[
    "{\"step_by_step_thinking\": \"Document 0 states that Baricitinib is a novel, FDA approved, once daily oral drug that is effective in combination with current treatment and results in significantly reduced symptoms with good safety profile. Document 1 also supports this by stating that the ACR20 response rate in the baricitinib group was significantly higher compared with that in the control group at 12 weeks and 24 weeks. Document 2 also mentions that Baricitinib improved RA control as determined by American College of Rheumatology 20% (RR, 2.03; 95% CI, 1.87 to 2.20) and Health Assessment Questionnaire-Disability Index scores (mean differences, -0.31; 95% CI, -0.34 to -0.28) compared with placebo. Document 3 also supports this by stating that Baricitinib provides an oral treatment option for patients failing tumor necrosis factor inhibitors (TNFis).\", \"answer_choice\": \"A\"}"
]